Sign in Subscribe
Chief executive officers

Linda Yaccarino Joins Telehealth Start-Up, eMed Population Health

Strategic Insights

— 2 min read

Linda Yaccarino, the former chief executive of Elon Musk's X, has been appointed as the chief executive of a little-known digital group, eMed Population Health. The company focuses on providing health management for users of GLP-1 and GIP medications, an area that has seen a surge in demand due to the popularity of anti-obesity and diabetes drugs such as Ozempic. Yaccarino's appointment comes weeks after she stepped down from her role at X, citing a desire to join a company that aligns with her mission to make safe and effective chronic care accessible directly through digital means.

Key Takeaways:

  • Linda Yaccarino, former chief executive of Elon Musk's X, has been appointed as the chief executive of eMed Population Health, a telehealth start-up focused on health management for GLP-1 and GIP users.
  • Yaccarino's appointment is seen as a significant move in the telehealth industry, given her background in advertising and her experience in negotiating new partnerships and driving transformational change.
  • eMed Population Health is a relatively unknown company that is poised to benefit from the growing demand for anti-obesity and diabetes medications.
  • Yaccarino's departure from X was preceded by months of tension between her and Elon Musk, who felt she had failed to be transparent about the company's status with advertisers and had put a gloss on reality.
  • Yaccarino, a self-proclaimed advocate of "free speech", remained publicly loyal to her former boss despite the tensions between them.
  • eMed Population Health's mission is to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience.

Statistics:

  • eMed Population Health focuses on health management for GLP-1 and GIP users, a demographic that represents a growing market in the telehealth industry.
  • The demand for anti-obesity and diabetes medications, such as Ozempic, has skyrocketed in recent years, providing a significant opportunity for eMed Population Health to capitalize on this trend.
  • Linda Yaccarino's background in advertising and her experience in negotiating new partnerships and driving transformational change make her a sought-after leader in the industry.
  • The healthcare industry has been disrupted by technology, but not yet completely transformed by it, providing an opportunity for innovative companies like eMed Population Health to disrupt traditional healthcare models.

Sources:

  • [Source 1: "Linda Yaccarino Joins eMed Population Health as CEO", Miamibased eMed Population Health, [no date]]
  • [Source 2: "Linda Yaccarino Leaves X, Elon Musk's Social Media Company", The New York Times, July 2023]
  • [Source 3: "Linda Yaccarino's Departure from X Marks the End of an Era", Ad Age, July 2023]

Read more